| Biomarker ID | 1067 |
| PMID | 23391636 |
| Year | 2013 |
| Biomarker | KLK15 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in Stage pT3/4 (2.71 Median fold difference) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include: PPAR Alpha Pathway WP2878, Nuclear Receptors Meta-Pathway WP2882 |
| Experiment | Stage pT2 Vs Stage pT3/4 |
| Type of Biomarker | Diagnostic |
| Cohort | 72 patients with Stage 2 and 88 with Stage 3 or 4 were chosen for the study |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.032 |
| Method Used | NA |
| Clinical | No |
| Remarks | Expression Values are shown as: log10copies/μg total RNA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |